Wed, Apr-24-19, 13:09
|
Senior Member
Posts: 1,469
|
|
Plan: Banting
Stats: 302/187/187
BF:
Progress: 100%
Location: New Zealand
|
|
How reliable is the statistical evidence for limiting saturated fat intake?
Here's a new re-analysis by Simon Thornley, Grant Schofield, Caryn Zinn and George Henderson of another meta-analysis commonly cited as evidence for reducing saturated fat intake. It turns out that when you crunch the numbers differently and account for publication bias, there is no association between saturated fat consumption and CVD risk after all:
Quote:
Introduction
Evidence from meta‐analyses has been influential in deciding whether or not limiting saturated fat intake reduces the incidence of cardiovascular disease. Recently, random effects analyses have been criticised for exaggerating the influence of publication bias, and an alternative proposed which obviates this issue: “inverse‐variance heterogeneity”. We re‐analysed the influential Hooper meta‐analysis which supports limiting saturated fat intake to decide whether or not the results of the study were sensitive to the method used.
Methods
Inverse‐variance heterogeneity analysis of this summary study was carried out and the results contrasted with standard methods. Publication bias was also considered.
Results
Inverse variance heterogeneity analysis of the Hooper combined‐CVD end point results returned a pooled relative risk of 0.93 (95% confidence interval: 0.74 to 1.16). This finding contrasts with the traditional random effects analysis with the corresponding statistic of 0.93 (95% confidence interval: 0.88 to 0.98). Egger tests, funnel and Doi plots along with recently published suppressed trial results suggest that publication bias is present.
Conclusions
This study questions the use of the Hooper study as evidence to support limiting saturated fat intake. Our re‐analysis, together with concordant results from other meta‐analyses of trials indicate that routine advice to reduce saturated fat intake in people with (or at risk for) cardiovascular disease be reconsidered.
|
https://doi.org/10.1111/imj.14325
|